Astrocytoma

• 

  Subject Areas on Research

  • 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. 
  • A case of Ollier's disease associated with two intracranial gliomas. 
  • A glial fibrillary acidic protein-expressing and tumorigenic cell line derived from an avian sarcoma virus-induced rat astrocytoma. 
  • A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. 
  • A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study. 
  • Acquired stuttering due to recurrent anaplastic astrocytoma. 
  • An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium. 
  • An intermediate filament-associated protein, p50, recognized by monoclonal antibodies. 
  • Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. 
  • Benzodiazepine and beta-adrenergic receptor ligands independently stimulate phospholipid methylation. 
  • Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. 
  • Brain tumor types induced by the Schmidt-Ruppin strain of Rous sarcoma virus in inbred Fischer rats. 
  • Brain tumors induced in dogs by the Schmidt-Ruppin strain of Rous sarcoma virus. Neuropathological and immunological observations. 
  • CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. 
  • Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy. 
  • Cell adhesion to fibronectin and tenascin: quantitative measurements of initial binding and subsequent strengthening response. 
  • Cellular immunity in rats with primary brain tumors: inhibition of macrophage migration by soluble extracts of avian sarcoma virus-induced tumors. 
  • Cerebral blood flow in a rat glioma model during halothane anesthesia. 
  • Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. 
  • Chemotherapy for pilocytic astrocytomas. 
  • Chromosomal characteristics of childhood brain tumors. 
  • Clinical characteristics and treatment of malignant brainstem gliomas in elderly patients. 
  • Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. 
  • Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. 
  • Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. 
  • Comparison of intensity-modulated tomotherapy with stereotactically guided conformal radiotherapy for brain tumors. 
  • Computed tomography of virally induced canine brain tumors: a preliminary report. 
  • Constrained customization of non-coplanar beam orientations in radiotherapy of brain tumours. 
  • Conventional external beam radiotherapy for central nervous system malignancies. 
  • Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma. 
  • Correlation of neuropathologic findings, computerized tomographic and high-resolution ultrasound scans of canine avian sarcoma virus-induced brain tumors. 
  • Cortical localization of temporal lobe language sites in patients with gliomas. 
  • Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor. 
  • Cyclophosphamide for the treatment of progressive low-grade astrocytoma: a Pediatric Oncology Group phase II Study. 
  • Differential Apaf-1 levels allow cytochrome c to induce apoptosis in brain tumors but not in normal neural tissues. 
  • Differential expression of ros oncogene in primary human astrocytomas and astrocytoma cell lines. 
  • Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. 
  • Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab. 
  • ECT in the presence of brain tumor and increased intracranial pressure: evaluation and reduction of risk. 
  • EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. 
  • EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. 
  • Effectiveness of radiotherapy for elderly patients with anaplastic gliomas. 
  • Enhanced optical imaging of rat gliomas and tumor margins. 
  • Evaluation of apparent diffusion coefficient thresholds for diagnosis of medulloblastoma using diffusion-weighted imaging. 
  • Everolimus tablets for patients with subependymal giant cell astrocytoma. 
  • Exomic sequencing of four rare central nervous system tumor types. 
  • FDG-PET in the selection of brain lesions for biopsy. 
  • Factors influencing the cell type of brain tumors induced in dogs by Schmidt-Ruppin Rous sarcoma virus. 
  • False-positive MRI detection of recurrent or metastatic pediatric infratentorial tumors. 
  • False-positive spinal MR findings for subarachnoid spread of primary CNS tumor in postoperative pediatric patients. 
  • Gender differences in facial expression recognition in survivors of pediatric brain tumors. 
  • General immunocompetence of rats bearing avian sarcoma virus-induced intracranial tumors. 
  • Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. 
  • Glioma-associated antigens defined by monoclonal antibodies against an avian sarcoma virus-induced rat astrocytoma. 
  • Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. 
  • Gliomatosis cerebri: cytologic and autopsy findings in a case involving the entire neuraxis. 
  • Glutathione S-transferase polymorphisms and survival in primary malignant glioma. 
  • Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines. 
  • Histologically benign, clinically aggressive: Progressive non-optic pathway pilocytic astrocytomas in adults with NF1. 
  • Human brain glycogen phosphorylase. Cloning, sequence analysis, chromosomal mapping, tissue expression, and comparison with the human liver and muscle isozymes. 
  • Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. 
  • IDH1 and IDH2 mutations in gliomas. 
  • INTRACRANIAL TUMORS IN INFANCY AND CHILDHOOD. A CLINICAL STUDY OF TWENTY CASES. 
  • Identification of distinct and overlapping cortical areas for bilingual naming and reading using cortical stimulation. Case report. 
  • Identification of glial filament protein and vimentin in the same intermediate filament system in human glioma cells. 
  • Immunobiology of malignant astrocytomas. 
  • Immunobiology of primary intracranial tumors. 
  • Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. 
  • Immunohistochemical study of glial fibrillary acidic protein in avian sarcoma virus-induced gliomas in dogs. 
  • Impact of tumor histology on resectability and neurological outcome in primary intramedullary spinal cord tumors: a single-center experience with 102 patients. 
  • Improved survival in the largest national cohort of adults with cerebellar versus supratentorial low-grade astrocytomas. 
  • Induction of transformational changes in normal endothelial cells by cultured human astrocytoma cells. 
  • Infiltrating spinal cord astrocytomas: Epidemiology, diagnosis, treatments and future directions. 
  • Influence of age at inoculation on avian oncornavirus-induced brain tumor incidence, tumor morphology, and postinoculation survival in F344 rats. 
  • Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. 
  • Irinotecan therapy in adults with recurrent or progressive malignant glioma. 
  • Leptomeningeal dissemination of optic pathway gliomas in three children. 
  • Low-grade astrocytomas: the prognostic value of fibrillary, gemistocytic, and protoplasmic tumor histology. 
  • Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response. 
  • Lymphocyte subpopulations and responsiveness in rats bearing intracranial tumors induced by avian sarcoma virus. 
  • Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. 
  • Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation. 
  • Malignant supratentorial glial-neuronal neoplasms: report of two cases and review of the literature. 
  • Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. 
  • Metabolomic profiling of sphingolipids in human glioma cell lines by liquid chromatography tandem mass spectrometry. 
  • Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. 
  • Molecular markers of prognosis in astrocytic tumors. 
  • Molecular pathogenesis of malignant gliomas. 
  • Molecular profiling of different glioma specimens from an Ollier disease patient suggests a multifocal disease process in the setting of IDH mosaicism. 
  • Monoclonal antibodies reactive with epitopes restricted to glial fibrillary acidic proteins of several species. 
  • Morphologic and molecular genetic aspects of oligodendroglial neoplasms. 
  • Morphologic observations of brain tumors in PD4 hamsters induced by four strains of avian sarcoma virus. 
  • Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. 
  • Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. 
  • Mutant metabolic enzymes are at the origin of gliomas. 
  • Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. 
  • Neuronal-astrocyte metabolic interactions: understanding the transition into abnormal astrocytoma metabolism. 
  • Oligodendroglioma and juvenile pilocytic astrocytoma presenting as synchronous primary brain tumors. Case report with histological and molecular differentiation of the tumors and review of the literature. 
  • Osteoblastic metastases from astrocytomas: a report of two cases. 
  • Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. 
  • Partial purification and characterization of a murine glioma-associated antigen defined by syngeneic rat monoclonal antibodies. 
  • Patterns of the early, gross chromosomal changes in malignant human gliomas. 
  • Pediatric brain stem tumors: patterns of treatment failure and their implications for radiotherapy. 
  • Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. 
  • Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. 
  • Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. 
  • Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. 
  • Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. 
  • Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. 
  • Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms. 
  • Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. 
  • Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. 
  • Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. 
  • Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. 
  • Phospholipid methylation: a possible mechanism of signal transduction across biomembranes. 
  • Pilocytic astrocytoma: correlation between the initial imaging features and clinical aggressiveness. 
  • Postradiation cerebellar necrosis mimicking tumor: MR appearance. 
  • Prognostic value of magnetic resonance imaging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect. 
  • Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. 
  • Purification and biochemical characterization of gamma-glutamylcysteine synthetase from a human malignant astrocytoma cell line. 
  • R-type virus-like particles in avian sarcoma virus-induced rat central nervous system tumors. 
  • Recent advances in intradural spinal tumors. 
  • Recent advances in the treatment of malignant astrocytoma. 
  • Recurrent brain tumors in children. 
  • Redox properties of cytochrome oxidase and vascular reactivity of astrocytomas and neuroblastomas in vivo. 
  • Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. 
  • Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. 
  • Relationship of the demonstration of intermediate filament protein to kinetics of three human neuroepithelial tumor cell lines. Lack of neural-related proteins in most cells in S phase: a double-labeled immunohistochemical study on matrix cultures. 
  • Resolution of exudative retinal detachment from retinal astrocytoma following photodynamic therapy. 
  • Sequential adsorption analysis of antibodies to neuroectodermal cells by an indirect quantitative method. 
  • Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. 
  • Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival. 
  • Social functioning and facial expression recognition in survivors of pediatric brain tumors. 
  • Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours. 
  • Somatosensory evoked potentials in a patient with a cervical glioma and syrinx. 
  • Specificity, cross-reactivity, and affinity of 125I-labeled antiglioma antibodies for monolayers of cultured glioma cells. 
  • Spinal cord astrocytomas: a modern 20-year experience at a single institution. 
  • Spontaneous hemorrhage associated with a pilomyxoid astrocytoma. Case report. 
  • Structural analysis of a human glial variant laminin. 
  • Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. 
  • Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide. 
  • Susceptibility of inbred Fischer rats to brain tumor induction by Rous sarcoma virus. 
  • Targeted radiotherapy of brain tumours. 
  • Targeting the Tie2/Tek receptor in astrocytomas. 
  • Temozolomide and treatment of malignant glioma. 
  • Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. 
  • Temozolomide in pediatric low-grade glioma. 
  • Temporal lobe hypometabolism on PET: predictor of seizure control after temporal lobectomy. 
  • The Effects of Thermal Preconditioning on Oncogenic and Intraspinal Cord Growth Features of Human Glioma Cells. 
  • The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. 
  • The fine structure of canine gliomas and intracranial sarcomas induced by the Schmidt-Ruppin strain of the Rous sarcoma virus. 
  • The fine structure of intracranial neoplasms induced by the inoculation of avian sarcoma virus in neonatal and adult rats. 
  • The genetic landscape of anaplastic astrocytoma. 
  • The human glutathione S-transferase P1 protein is phosphorylated and its metabolic function enhanced by the Ser/Thr protein kinases, cAMP-dependent protein kinase and protein kinase C, in glioblastoma cells. 
  • The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. 
  • The induction of intractranial neoplasms by the inoculation of avian sarcoma virus in perinatal and adult rats. 
  • The role of the subependymal plate in avian sarcoma virus brain tumor induction: comparison of incipient tumors in neonatal and adult rats. 
  • The use of fluorescein sodium in the biopsy and gross-total resection of a tectal plate glioma. 
  • Transformation of juvenile pilocytic astrocytoma to anaplastic pilocytic astrocytoma in patients with neurofibromatosis type I. 
  • Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. 
  • Tumor antigens in astrocytic gliomas. 
  • Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). 
  • Unusual presentations of inflammatory conditions in cerebrospinal fluid. 
  • Use of Apparent Diffusion Coefficient Values for Diagnosis of Pediatric Posterior Fossa Tumors. 
  • Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation. 
  • Well differentiated astrocytoma occurring nine years after radiation therapy for medulloblastoma. 
  • Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. 
  • XRCC3 haplotypes and risk of gliomas in a Chinese population: a hospital-based case-control study. 
• 

  Keywords of People

  • Diplas, Bill, Student, Pathology
  • Erickson, Harold Paul, James B. Duke Professor of Cell Biology, Biomedical Engineering
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Turner, Dennis Alan, Professor of Neurosurgery, Biomedical Engineering
  • Warner, David Samuel, Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology
  • Yan, Hai, Henry S. Friedman Professor of Neuro-Oncology in the School of Medicine, Pathology